IS BONE-MARROW EXAMINATION IN SMALL-CELL LUNG-CANCER REALLY NECESSARY
IS BONE-MARROW EXAMINATION IN SMALL-CELL LUNG-CANCER REALLY NECESSARY
复制标题
DOI：
10.7326/0003-4819-105-4-508
复制
发表时间：
1986-10-01
影响因子：
39.2
通讯作者：
EVANS, WK
中科院分区：
文献类型：
--
作者：
CAMPLING, B;QUIRT, I;EVANS, WK
在403例小细胞肺癌患者中，我们通过抽吸、活检或两者结合确定了67例骨髓受累，并发现这两种方法在检测骨髓受累方面是互补的。阳性活检标本的平均表面积显著大于随机选择的阴性活检标本组，表明标本越大，检测肿瘤的机会越大。与其他广泛疾病患者相比，骨髓受累患者的预后仅略差。仅基于骨髓受累，403例患者中仅7例（1.7%）存在广泛疾病。由于骨髓检查很少改变非侵入性评估患者的癌症分期，对化疗的耐受性没有影响，对生存期的影响也很小，因此我们不建议在小细胞肺癌的常规分期中使用这种方法。
Of 403 patients with small-cell lung cancer, we identified by aspiration, biopsy, or both 67 with bone marrow involvement and found the two procedures to be complementary in detecting marrow involvement. The mean surface area of the positive biopsy specimens was significantly greater than that of a randomly selected group of negative biopsy specimens, suggesting that the larger the specimen, the greater the chance of detecting tumour. Patients with marrow involvement had only a slightly worse prognosis compared with other patients who had extensive disease. Only 7 of the 403 patients (1.7%) had extensive disease based on marrow involvement alone. Because bone marrow examination rarely changes the stage of cancer in noninvasively assessed patients, and has no impact on the tolerance of chemotherapy and only a small effect on length of survival, we do not recommend this procedure in the routine staging of small-cell lung cancer.